2017 MassBio Annual Meeting March 30, 2017 8:00 AM – March 31, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA
Reporter: Aviva Lev-Ari, PhD, RN
Leaders in Pharmaceutical Business Intelligence will cover the event
will be streaming content using Social Media from the Royal Sonesta Boston on 3/30 and 3/31 in
2017 MassBio Annual Meeting
The MassBio Annual Meeting focuses on the timeliest and critical challenges facing the Massachusetts life sciences industry. The meeting program is designed by a steering committee of industry leaders and the agenda encompasses keynote presentations, panel discussions, interactive working sessions and extensive networking opportunities.
The MassBio Annual Meeting also includes the Innovative Leadership Award Luncheon, which honors an industry leader for his or her contribution to moving the life sciences industry forward.
UPDATED on 3/2/2017
Governor Charlie Baker to Address MassBio’s Annual Meeting
MassBio is thrilled to announce that Governor Charlie Baker will address attendees of MassBio’s 2017 Annual Meeting, which focuses on the most critical challenges facing the Massachusetts life sciences industry.
Check out some recent news stories on Governor Baker:
CBS Boston, 2/28/2017
The Boston Globe, 2/4/2017
Annual Meeting Highlights:
Keynote Speaker Dan Schorr:
“Many people ask me, ‘What did you learn from Cancer?’ The lessons range from ‘Be Present’ — I was always a long term planner–to ‘Cut Em Lose’ — anyone in my life that said, ‘It Sucks’ or added stress, no matter who they were, was immediately cut off. I still apply those lessons today and there are many more of them. But I was hiking one day making a mental list of Lessons from Cancer and the more daunting question came up, ‘Why did I survive?’ Those answers are the takeaway from the session.”
New Convergence Track:
This new track will offer high-level discussions on the convergence of diagnostics, infotechnology and data mining for precision medicine. We’ll examine the growth in technology and why a focus on IT is crucial to business practices. With Massachusetts at the forefront of industry advancements, Boston-specific endeavors will be showcased.
- Funding Issues
- Big Data Analysis
- Biotech in the Era of Real-World Evidence
- Emerging Markets in the Global Landscape
- CRISPR and What’s Next
- …and more!
Contact Erica Feinberg for sponsorship opportunities.
Value: Biotech in the Era of Real-World Evidence
It is a time of great change in healthcare, as patients seek insight and engagement in the development of treatments, policymakers disagree on whether to regulate the industry more or less, and the market shifts from volume-based to value-based payment models. With scientific discovery advancing faster than innovations to our insurance and payment models, how do biopharma companies plan for bringing new treatments to market?
We will discuss the trends toward convergence in drugs, diagnostics, devices and digital health
Cancer Moonshot: Where Des it Go From Here?
Better Business Track
The Next Generation
What are the challenges facing young researchers and new entrepreneurs today? We’ will discuss workforce development, diversity, the funding environment and more.
Changes in the Valley of Death
There is much hand-wringing over the challenges of getting early-stage funding today. But there has always been a “valley of death” in biotech. How is today’s valley different than in years past? Is it really harder to raise money today? How is the diverse and fragmented funding environment making the process harder or easier?
Emerging Markets in the Global Landscape
How are emerging markets and today’s global landscape impacting biopharma strategy?
Trends in Science Track
We will discuss current research and trends in Parkinson’s, Alzheimer’s, and other CNS diseases
CRISPR and What’s Next
A look at where CRISPR technology is heading and the next generation of gene editing tools (CAS9, Cpf1, etc.)
Pain & Addiction
We all understand the devastation that prescription drug addiction is causing in our society. But we can’t eliminate addiction until we discover a non-addictive method for treating pain. What’s next for pain?
As the population ages and lives longer, there is significant opportunity in research and treating diseases of aging. We will discuss osteoarthritis, hearing loss, Alzheimer’s, dementia and other health conditions related to aging.
Convergence Track (New for 2017!)
Funding Issues at the Intersections
Despite the hype about cross-industry collaboration and convergence, it is hard to raise money for technologies at the intersections of these industries. Who is funding convergent ideas and how do you sell them?
Big Data Analytics Possibilities
Next Generation Diagnostics